Blueprint Medicines Corp. - BPMC Quarterly EPS earnings growth

Corporate company logo of Blueprint Medicines Corp. (BPMC)

Stable demand for innovative medicine makes Blueprint Medicines (BPMC) a defensive asset independent of macroeconomic factors. Quarterly EPS variation confirms this resilience, with the metric holding around -99.40. Revenue growth from Ayvakit and new indications for mastocytosis are driving the momentum. The strategy is based on developing precision kinase inhibitors for the therapy of rare genetic mutations.

blueprintmedicines.com (BPMC) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 08/02/2025

Analytical breakdowns for Blueprint Medicines

- share price and consensus valuation forecast:
Fundamental company valuation:Blueprint Medicines Corp. - BPMC
Flagship merchandise of Blueprint Medicines Corporation

This indicator measures the quarterly growth rate of net earnings per share, serving as a filter to exclude fundamentally weak issuers and assess alpha potential. By analyzing the quarterly EPS trend, an investor can determine how effectively Blueprint Medicines (BPMC) converts investments in leading oncologists and R&D resources into actual financial results, which is critical for minimizing portfolio drawdown risks.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ELVN (Enliven Therapeutics, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share growth for the trailing year Relay Pharma|Nurix Therapeutics Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Biosciences|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|GLUE: Year-over-year earnings per share growth rate for the last twelve months|CGEM (cullinanoncology.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immuneering Inc. IMRX|Quarterly EPS earnings growth CCCC|Black Diamond Therapeutics - Year-over-year earnings per share growth for the last 12 months|Repare Therapeutics Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months PMVP|KPTI: Year-over-year net earnings per share growth for the last 12 months|propanc.com - Year-over-year earnings per share growth rate for the last twelve months|BGMS: Quarterly EPS earnings growth|Aadi Bioscience Inc - Year-over-year earnings per one share growth for the last 12 months|ALRN (Aileron Therapeutics Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)